Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study on the benefits and risks of ticagrelor in maintenance hemodialysis patients
ChiCTR2600125501Phase 3Completed
- Sponsor
- Second Affiliated Hospital of Guangdong Medical University
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ticagrelor in acute coronary syndrome (ACS), brain infarction, cardiac morbidity and 1 more (2 arms), sponsored by Second Affiliated Hospital of Guangdong Medical University. Primary endpoint: Composite endpoint of non-fatal acute coronary syndrome and acute cerebral infarction. Started May 2026; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)brain infarctioncardiac morbiditycerebrovascular disease
Beyond the preview
Go deeper on ChiCTR2600125501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125501.